Urology
Volume 67, Issue 6 , Pages 1235-1240, June 2006

Response to second-line chemotherapy in patients with hormone refractory prostate cancer receiving two sequences of mitoxantrone and taxanes

Presented in part at the 2005 Annual Meeting of the American Society of Clinical Oncology, Orlando, Florida.

Lank Center for Genitourinary Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts

Received 11 October 2005; accepted 4 January 2006.

To access this article, please choose from the options below

Login to an existing account or Register a new account.

  • Purchase this article for 31.50 USD (You must login/register to purchase this article)

    Online access for 24 hours. The PDF version can be downloaded as your permanent record.

  • Subscribe to this title

    Get unlimited online access to this article and all other articles in this title 24/7 for one year.

  • Claim access now

    For current subscribers with Society Membership or Account Number.

  • Visit SciVerse ScienceDirect to see if you have access via your institution.

 This work was supported by the Richard Almy Fund for Prostate Cancer, the C. Brendan Noonan, Jr Charitable Foundation, and the Arthur and Linda Gelb Center for Translational Medicine.

PII: S0090-4295(06)00068-9

doi:10.1016/j.urology.2006.01.006

Urology
Volume 67, Issue 6 , Pages 1235-1240, June 2006

Article Tools

* Image Usage & Resolution